<DOC>
	<DOCNO>NCT01489228</DOCNO>
	<brief_summary>This study ass safety efficacy E1224 , pro-drug ravuconazole , individual chronic indeterminate Chagas disease recruit research centre Tarija Cochabamba , Bolivia .</brief_summary>
	<brief_title>Proof-of-Concept Study E1224 Treat Adult Patients With Chagas Disease</brief_title>
	<detailed_description>Chagas disease ( CD ) rank among world 's neglected disease . In Latin America , 21 country endemic CD estimate 108 million people risk contract disease . Estimates 1980s indicate 16 million 18 million individual infect . In 1990s , series multinational control initiative , estimate number infect people revise 9.8 million 2001 . The estimate burden disease term disability-adjusted life year ( DALYs ) decline 2.7 million 1990 586,000 2001 . Recent estimate Pan American Health Organization ( PAHO , 2006 ) indicate 7.54 million infected people 55,185 new case per year . The two medicine available - benznidazole ( BZN ) nifurtimox ( NFX ) - know cause serious toxicity unsatisfactory cure rate , especially use adult chronic CD patient . Novel antifungal triazole derivative arise alternative treatment CD . They inhibit T. cruzi ergosterol biosynthesis , essential parasite growth survival , pharmacokinetic property suitable treatment disseminate intracellular infection . Several triazole derivative test animal model CD , include D08701 , posaconazole , ravuconazole ( RAV ) , albaconazole , TAK-187 . In particular , RAV previously show potent vitro vivo activity , induce parasitological cure mouse acute infection , include cause benznidazole-resistant strain T. cruzi . Suppressive activity also see dog model . E1224 water-soluble monolysine salt form RAV pro-drug . It broad-spectrum triazole antifungal vitro activity Candida Aspergillus specie , non-Aspergillus specie filamentous fungi , Cryptococcus , dermatophytes , fungi cause endemic mycoses . RAV evaluate extensively animal model human trial include Phase 2 safety efficacy trial oropharyngeal esophageal candidiasis onychomycosis , prevention invasive fungal infection hematopoietic stem cell transplant recipient . With benign safety profile encourage result animal study favorable pharmacokinetics , E1224 consider priority candidate clinical development treatment Chagas ' disease . The general objective phase II trial determine whether three different dose regimen E1224 efficacious safe eradicate T. cruzi parasitemia individual chronic indeterminate form CD , comparison placebo .</detailed_description>
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Benzonidazole</mesh_term>
	<criteria>Screening Criteria : Age &gt; 18 &lt; 50 year Weight &gt; 40 kg Diagnosis T. cruzi infection conventional serology ( minimum two three positive test [ enzyme link immunosorbent assay ( ELISA ) , indirect immunofluorescence ( IIF ) , hemagglutination inhibition ( HAI ) ] ) Signed , write informed consent form No sign and/or symptoms chronic cardiac and/or digestive form CD No acute chronic health condition may interfere efficacy and/or safety evaluation study drug No formal contraindication BZN E1224 No known history hypersensitivity , allergic , serious adverse reaction study drug No history CD treatment BZN NFX time past No history systemic treatment itraconazole , ketoconazole , posaconazole , isavuconazole , allopurinol past Confirmed diagnosis T. cruzi infection serial qualitative PCR AND Conventional serology Women reproductive age must negative serum pregnancy test screening , must breastfeed , consistently use and/or partner consistently use adequate contraceptive method Normal ECG screen Abnormal laboratory test value screen follow parameter : total White Blood Cells ( WBC ) count , platelet count , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , total bilirubin , creatinine ; gammaglutamyl transferase ( GGT ) History alcohol abuse drug addiction ( specify Study Manual Operations ) Any condition prevents patient take oral medication Any concomitant use antimicrobial antiparasitic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Chagas Disease</keyword>
</DOC>